The objective of this project is to provide a facility for the production and safety testing of vaccine preparations intended for evaluation in the Vaccine, Treatment and Evaluation Units (VTEUs) of the Division of Microbiology and Infectious Diseases (DMID). The facility will also serve as a repository for specimens generated during DMID-supported Phase I, II, and III clinical trials. Specifically- this facility will accelerate the development of new and improved vaccines of public health importance. The work in this contract encompasses the development and pilot lot production, and related studies, of vaccines appropriate for human clinical trials. With an ever-growing number of NIAID supported clinical vaccine evaluations there is also a growing need for a central facility to systematically store, transport and track and increasing number of clinical specimens that are generated during DMID-supported clinical trials. The capacity to develop and produce a wide range of such candidates will enhance the ability of DMID to meet its expanding needs and better fulfill its mission by promoting and supporting preclinical and clinical research on vaccines that will improve the health of the public. Therefore- this contract will provide the capability for all aspects of development and pilot lot production, including safety testing, of a broad range of vaccine candidates (including viral, bacterial, parasitic and fungal preparations and subtractions consisting of polysaccharides, nucleic acids, lipoproteins, and/or synthetic or purified proteins (either linear or variations of branched multiple antigen preparations) intended for evaluation in humans as experimental vaccines.

Project Start
1996-09-30
Project End
2001-09-29
Budget Start
1998-09-22
Budget End
2000-09-29
Support Year
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Type
Schools of Medicine
DUNS #
660735098
City
Worcester
State
MA
Country
United States
Zip Code
01655
Roberts, Anjeanette; Thomas, William D; Guarner, Jeannette et al. (2006) Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J Infect Dis 193:685-92
Greenough, Thomas C; Carville, Angela; Coderre, James et al. (2005) Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus. Am J Pathol 167:455-63
Greenough, Thomas C; Babcock, Gregory J; Roberts, Anjeanette et al. (2005) Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis 191:507-14
Babcock, Gregory J; Esshaki, Diana J; Thomas Jr, William D et al. (2004) Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol 78:4552-60
Jeffers, Scott A; Tusell, Sonia M; Gillim-Ross, Laura et al. (2004) CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 101:15748-53
Carlton, J M; Yowell, C A; Sturrock, K A et al. (2001) Biomagnetic separation of contaminating host leukocytes from plasmodium-infected erythrocytes. Exp Parasitol 97:111-4